Phase II study of recombinant α-interferon in malignant melanoma

J. R. Neefe, S. S. Legha, A. Markowitz, S. Salmon, F. Meyskens, J. Groopman, M. Campion, L. Evans

    Research output: Contribution to journalArticlepeer-review

    21 Scopus citations


    Ninety-seven evaluable patients with measurable, advanced, malignant melanoma were treated with recombinant α interferon in a cooperative phase II efficacy trial, whose primary objective was to estimate the response rate. Interferon (rIFN α-2a, Roferon-A) was injected subcutaneously daily for 70 days. Dose was escalated in four steps from three million units to 36 million units over ten days. Eight patients responded objectively and six patients (6%) had a complete response. The median duration of complete response was 11 months. Patients achieving complete response had only cutaneous, nodal, or pulmonary disease; some had extensive prior therapy; some could tolerate no more than three million units per day. Few patients could tolerate the target dose of 36 million units daily for 70 days. Limiting toxicity was primarily fatigue. Interferon in tolerable doses is effective in a small subset of patients with melanoma. Comparison of published trials of dacarbazine and recombinant α interferon indicates the two drugs have similar activity.

    Original languageEnglish (US)
    Pages (from-to)472-476
    Number of pages5
    JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
    Issue number6
    StatePublished - 1990

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research


    Dive into the research topics of 'Phase II study of recombinant α-interferon in malignant melanoma'. Together they form a unique fingerprint.

    Cite this